June 15, 2021
The new Alzheimer’s drug Aduhelm (aducanumab) approved in the US last week is expected to pull in billions of dollars in yearly revenue, Eisai CEO Haruo Naito said on June 14. “It’ll definitely grow into a drug that generates billions...read more